Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease

Global Heart

Volumn 10, Issue 2, 2015, Pages 99-110

  Perel, Pablo ^a,b   Avezum, Alvaro ^c   Huffman, Mark ^d   Pais, Prem ^e   Rodgers, Anthony ^f   Vedanthan, Raj ^g   Wood, David ^h   Yusuf, Salim ⁱ  

^a WORLD HEART FEDERATION   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^d NORTHWESTERN UNIVERSITY   (United States)

^e ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^f GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; EDITORIAL; EVIDENCE BASED PRACTICE; HEALTH PROGRAM; HEART REHABILITATION; HUMAN; MEDICAL INFORMATION SYSTEM; MORBIDITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRESCRIPTION; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SECONDARY PREVENTION; SMOKING CESSATION; CORONARY ARTERY DISEASE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; HEALTH; HEALTH CARE PLANNING; MEDICAL SOCIETY; MORTALITY; PRACTICE GUIDELINE; STANDARDS; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AMERICAN HEART ASSOCIATION; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; GLOBAL HEALTH; GUIDELINES AS TOPIC; HEALTH PLANNING ORGANIZATIONS; HUMANS; MORBIDITY; TOBACCO USE CESSATION; UNITED STATES;

EID: 84948991519     PISSN: 22118160     EISSN: 22118179     Source Type: Journal    
DOI: 10.1016/j.gheart.2015.04.003     Document Type: Editorial

References (48)

1. S. Yusuf Two decades of progress in preventing vascular disease Lancet 360 2002 2 3
2. World Health Organization. World Health Report 2002: Reducing risks, promoting healthy life. Available at: www.who.int/whr/2002/en/whr02-en.pdf. Accessed March 27, 2015.
3. L. Chambless, U. Keil, A. Dobson et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONitoring of Trends and Determinants in Cardiovascular Disease Circulation 96 1997 3849 3859
4. A.J. Kerr, J. Broad, S. Wells, T. Riddell, R. Jackson Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart 95 2009 125 129
5. S.S. Lim, T.A. Gaziano, E. Gakidou et al. Prevention of cardiovascular disease in highrisk individuals in low-income and middle-income countries: health effects and costs Lancet 370 2007 1954 1962
6. S.C. Smith, E.J. Benjamin, R.O. Bonow et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation Circulation 124 2011 2458 2473
7. J. Perk, G. De Backer, H. Gohlke et al. European Guidelines on cardiovascular disease prevention in clinical practice (Version 2012) Eur Heart J 33 2012 1635 1701
8. World Health Organization. Prevention of recurrent heart attacks and strokes in low and middle income populations. Evidence-based recommendations for policy makers and health professionals. Available at: www.who.int/cardiovascular-diseases/resources/pub0402/en/. Accessed March 27, 2015.
9. J. Critchley, S. Capewell Smoking cessation for the secondary prevention of coronary heart disease Cochrane Database Syst Rev 4 2003 CD003041
10. S. Yusuf, S. Islam, C.K. Chow et al. Use of secondary prevention drugs for cardiovascular disease in the community in high income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey Lancet 378 2011 1231 1243
11. K. Teo, S. Lear, S. Islam et al. Prevalence of a Healthy Lifestyle Among Individuals with Cardiovascular Disease in High-, Middle- and Low-Income Countries. The Prospective Urban Rural Epidemiology (PURE) Study JAMA 309 2013 1613 1621
12. S. Yusuf, S. Rangarajan, K. Teo et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries N Engl J Med 371 2014 818 827
13. K. Kotseva, D. Wood, G. De Backer et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
14. T.M. Maddox, P.S. Chan, J.A. Spertus et al. Variation in secondary prevention prescription among outpatient cardiology practices: insights from the NCDR J Am Coll Cardiol 63 2014 539 546
15. Kotseva K, personal communication (EUROASPIRE IV).
16. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) 2009-2010. Available at: wwwn.cdc.gov/nchs/nhanes/search/nhanes09-10.aspx. Accessed March 27, 2015.
17. N. Dawood, V. Vaccarino, K.J. Reid et al. Predictors of Smoking Cessation After a Myocardial Infarction The Role of Institutional Smoking Cessation Programs in Improving Success Arch Intern Med 168 2008 1961 1967
18. R. Nieuwlaat, J.D. Schwalm, R. Khatib, S. Yusuf Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J 34 2013 1262 1269
19. K.A. Eagle, E. Kline-Rogers, S.G. Goodman et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study Am J Med 117 2004 73 81
20. D. Rasella, M.O. Harhay, M.L. Pamponet et al. Impact of primary health care on mortality from heart and cerebrovascular diseases in Brazil: a nationwide analysis of longitudinal data BMJ 348 2014 1 10
21. A. Clark, L. Hartling, B. Vandermeer, F. McAlister Secondary prevention programs for patients with coronary artery disease: A meta-analysis of randomized control trials Ann Intern Med 143 2005 659 672
22. K. Turk-Adawi, N. Sarrafzadegan, S.L. Grace Global availability of cardiac Rehabilitation Nat Rev Cardiol 10 2014 586 596
23. X. Jiang, J.W. Sit, T.K. Wong A nurse-led cardiac rehabilitation programme improves health behaviours and cardiac physiological risk parameters: evidence from Chengdu, China J Clin Nurs 16 2007 1886 1897
24. S. Lewin, J.N. Lavis, A.D. Oxman et al. Supporting the delivery of cost-effective interventions in primary health-care systems in low-income and middle-income countries: an overview of systematic reviews Lancet 372 2008 928 939
25. N. van Ginneken, P. Tharyan, S. Lewin et al. Non-specialist health worker interventions for the care of mental, neurological and substance-abuse disorders in low- and middle-income countries Cochrane Database Syst Rev 11 2013 CD009149
26. World Health Organization. Task-Shifting: rational redistribution of tasks among health workforce teams: global recommendations and guidelines. Available at: www.who.int/healthsystems/TTR-TaskShifting.pdf. Accessed March 27, 2015.
27. R. Joshi, M. Alim, A.P. Kengne et al. Task Shifting for Non- Communicable Disease Management in Low and Middle Income Countries - A Systematic Review PLoS ONE 9 2014 e103754
28. R. Joshi, C. Chow, P.K. Raju et al. The Rural Andhra Pradesh Cardiovascular Prevention Study JACC 59 2014 1188 1196
29. D.Y. Kamath, D. Xavier, R. Gupta et al. Rationale and design of a randomized controlled trial evaluating community health worker-based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD) Am Heart J 168 2014 690 697
30. J. Connor, N. Rafter, A. Rodgers Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review Bull World Health Organ 82 2004 935 939
31. N.J. Wald, M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419 1425
32. S. Yusuf, P. Pais, R. Afzal, D. Xavier, K. Teo, J. Eikelboom et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 9672 2009 1341 1351
33. J.M. Castellano, G. Sanz, J.L. Peñalvo et al. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project J Am Coll Cardiol 64 2014 2071 2082
34. Webster R, on behalf of the SPACE Collaboration. The Single Pill to Avert Cardiovascular Events (SPACE) Collaboration: Main results. Presented at the World Congress of Cardiology. Melbourne, Australia. May 4-7, 2014.
35. M. Huffman, S. Yusuf Polypills Essential Medicines for Cardiovascular Disease Secondary Prevention? J Am Coll Cardiol 63 2014 1368 1370
36. J.M. Grimshaw, M.P. Eccles, J.N. Lavis, S.J. Jill, J.E. Squires Knowledge translation of research findings Implement Sci 7 2012 50
37. Rasha Khatib personal communication (PURE Study)
38. L.M. Niëns, E. Van de Poel, A. Cameron, M. Ewen, R. Laing, W.B.F. Brouwer Practical measurement of affordability: an application to medicines Bull WHO 90 2012 219 227
39. C.B. Holmes, W. Coggin, D. Jamieson et al. Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs JAMA 304 2010 313 320
40. S.P. Kishore, R. Vedanthan, V. Fuster Promoting Global Cardiovascular Health Ensuring Access to Essential Cardiovascular Medicines in Low- and Middle-Income Countries J Am Coll Cardiol 57 2011 1980 1987
41. H.V. Hogerzeil, J. Liberman, V.J. Wirtz et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration Lancet 381 2013 680 689
42. M.A. Rashid, D. Edwards, F.M. Walter, J. Mant Medication taking in coronary artery disease: a systematic review and qualitative synthesis Ann Fam Med 2014 224 232
43. C. Free, G. Phillips, L. Galli et al. The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic review PLoS Med 10 2013 e1001362
44. T. Horvath, H. Azman, G.E. Kennedy, G.W. Rutherford Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection Cochrane Database Syst Rev 3 2012 CD009756
45. D.H. Smith, J.M. Kramer, N. Perrin et al. A randomized trial of direct-to-patient communication to enhance adherence to betablocker therapy following myocardial infarction Arch Intern Med 168 2008 477 483
46. E. Herrett, L. Smeeth, L. Walker, C. Weston MINAP Academic Group The Myocardial Ischaemia National Audit Project (MINAP) Heart 96 2010 1264 1267
47. T.M. Maddox, P.S. Chan, J.A. Spertus et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry) J Am Coll Cardiol 63 2014 539 546
48. S.A. Risch, V.D. Vicera, N.T. Glusenkamp et al. Documented medication use among coronary artery disease outpatients in India: Insights from PINNACLE India outpatient registry Circ Cardiovasc Qual Outcomes 7 2014 A179